Oxford Immunotec Ltd., an Oxford, UK-based manufacturer and marketer of T cell-based diagnostic tests, closed the second tranche of a $26m Series D financing.
The financing was led by NLV Partners, with additional participation from new investor Kaiser Permanente Ventures and existing investors Clarus Ventures, Wellington Partners, Kuwait-based National Technology Enterprises Company, SPARK Ventures, DFJ Esprit, Oxford University and The Dow Chemical Company.
In connection with the financing, Vijay Lathi, a managing director at NLV Partners, has joined Oxford Immunotec’s board of directors. Jonathan Gee, Ph.D., a director at SPARK Ventures, also joined the board, following the close of the first tranche of the financing in July 2009.
The new capital will support advancement of the company’s diagnostic product pipeline and the ongoing commercialization of the T-SPOT®.TB test, which is a laboratory-based, cellular blood test designed to diagnose both latent tuberculosis (TB) infection and active disease by measuring T cells that have been activated specifically by Mycobacterium tuberculosis (MTB) antigens.
It is currently marketed in the United States, Europe, Canada and more than 40 other countries worldwide.
Oxford Immunotec US operations are based in Marlborough, MA.